{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:14:47Z","timestamp":1793056487746,"version":"4.5.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013748","name":"Hope Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clgc.2025.102453","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:59:58Z","timestamp":1760540398000},"page":"102453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7262-5528","authenticated-orcid":false,"given":"Prateek","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Arsalan Ahmed","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8165-6359","authenticated-orcid":false,"given":"Nikita","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Japneet K","family":"Oberoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Abdullah","family":"Humayun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9480-2626","authenticated-orcid":false,"given":"Yousef","family":"Zakharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0319-0239","authenticated-orcid":false,"given":"Jacob J","family":"Orme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1862-8467","authenticated-orcid":false,"given":"Adam","family":"Kase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7643-2836","authenticated-orcid":false,"given":"Dan S","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5376-4835","authenticated-orcid":false,"given":"Ruqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irbaz B","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8548-6948","authenticated-orcid":false,"given":"Parminder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clgc.2025.102453_bib0001","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1007\/s10147-024-02526-y","article-title":"Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution","volume":"29","author":"Kawashima","year":"2024","journal-title":"Int J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2025.102453_bib0002","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.urolonc.2024.07.006","article-title":"Novel therapeutic regimens in previously untreated metastatic urothelial carcinoma: a systematic review and Bayesian network meta-analysis","volume":"42","author":"Hinojosa-Gonzalez","year":"2024","journal-title":"Urol Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2025.102453_bib0003","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41585-024-00872-0","article-title":"The evolving treatment landscape of metastatic urothelial cancer","volume":"21","author":"Roviello","year":"2024","journal-title":"Nat Rev Urol"},{"issue":"10","key":"10.1016\/j.clgc.2025.102453_bib0004","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102453_bib0005","doi-asserted-by":"crossref","DOI":"10.1177\/1756287220980192","article-title":"Enfortumab vedotin in urothelial cancer","volume":"12","author":"Alt","year":"2020","journal-title":"Ther Adv Urol"},{"issue":"17","key":"10.1016\/j.clgc.2025.102453_bib0006","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.3390\/cancers16173071","article-title":"Mechanistic insights into the successful development of combination therapy of enfortumab vedotin and pembrolizumab for the treatment of locally advanced or metastatic urothelial cancer","volume":"16","author":"Taylor","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.clgc.2025.102453_bib0007","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1158\/1078-0432.CCR-24-1393","article-title":"FDA approval summary: enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma","volume":"30","author":"Brave","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.clgc.2025.102453_bib0008","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/SLA.0b013e31822a7047","article-title":"Cancer trials versus the real world in the United States","volume":"254","author":"Al-Refaie","year":"2011","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.clgc.2025.102453_bib0009","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40262-024-01369-0","article-title":"Clinical pharmacology of the antibody-drug conjugate enfortumab vedotin in advanced urothelial carcinoma and other malignant solid tumors","volume":"63","author":"Tang","year":"2024","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.clgc.2025.102453_bib0010","first-page":"4892","article-title":"Effects of hepatic or renal impairment on the pharmacokinetics of immune checkpoint inhibitors","volume":"12","author":"Zhao","year":"2022","journal-title":"Am J Cancer Res"},{"issue":"19","key":"10.1016\/j.clgc.2025.102453_bib0011","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T21:09:11Z","timestamp":1770671351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1558767325001533"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102453","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102453","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102453"}}